Cargando…

Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients

The kidney has a vital role in magnesium homeostasis and, although the renal handling of magnesium is highly adaptable, this ability deteriorates when renal function declines significantly. In moderate chronic kidney disease (CKD), increases in the fractional excretion of magnesium largely compensat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cunningham, John, Rodríguez, Mariano, Messa, Piergiorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455820/
https://www.ncbi.nlm.nih.gov/pubmed/26069820
http://dx.doi.org/10.1093/ndtplus/sfr166
_version_ 1782374775510794240
author Cunningham, John
Rodríguez, Mariano
Messa, Piergiorgio
author_facet Cunningham, John
Rodríguez, Mariano
Messa, Piergiorgio
author_sort Cunningham, John
collection PubMed
description The kidney has a vital role in magnesium homeostasis and, although the renal handling of magnesium is highly adaptable, this ability deteriorates when renal function declines significantly. In moderate chronic kidney disease (CKD), increases in the fractional excretion of magnesium largely compensate for the loss of glomerular filtration rate to maintain normal serum magnesium levels. However, in more advanced CKD (as creatinine clearance falls <30 mL/min), this compensatory mechanism becomes inadequate such that overt hypermagnesaemia develops frequently in patients with creatinine clearances <10 mL/min. Dietary calcium and magnesium may affect the intestinal uptake of each other, though results are conflicting, and likewise the role of vitamin D on intestinal magnesium absorption is somewhat uncertain. In patients undergoing dialysis, the effect of various magnesium and calcium dialysate concentrations has been investigated in haemodialysis (HD) and peritoneal dialysis (PD). Results generally show that dialysate magnesium, at 0.75 mmol/L, is likely to cause mild hypermagnesaemia, results for a magnesium dialysate concentration of 0.5 mmol/L were less consistent, whereas serum magnesium levels were mostly normal to hypomagnesaemic when 0.2 and 0.25 mmol/L were used. While dialysate magnesium concentration is a major determinant of HD or PD patients’ magnesium balance, other factors such as nutrition and medications (e.g. laxatives or antacids) also play an important role. Also examined in this review is the role of magnesium on parathyroid hormone (PTH) levels in dialysis patients. Although various studies have shown that patients with higher serum magnesium tend to have lower PTH levels, many of these suffer from methodological limitations. Finally, we examine the complex and often conflicting results concerning the interplay between magnesium and bone in uraemic patients. Although the exact role of magnesium in bone metabolism is unclear, it may have both positive and negative effects, and it is uncertain what the optimal magnesium levels are in uraemic patients.
format Online
Article
Text
id pubmed-4455820
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-44558202015-06-11 Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients Cunningham, John Rodríguez, Mariano Messa, Piergiorgio Clin Kidney J Articles The kidney has a vital role in magnesium homeostasis and, although the renal handling of magnesium is highly adaptable, this ability deteriorates when renal function declines significantly. In moderate chronic kidney disease (CKD), increases in the fractional excretion of magnesium largely compensate for the loss of glomerular filtration rate to maintain normal serum magnesium levels. However, in more advanced CKD (as creatinine clearance falls <30 mL/min), this compensatory mechanism becomes inadequate such that overt hypermagnesaemia develops frequently in patients with creatinine clearances <10 mL/min. Dietary calcium and magnesium may affect the intestinal uptake of each other, though results are conflicting, and likewise the role of vitamin D on intestinal magnesium absorption is somewhat uncertain. In patients undergoing dialysis, the effect of various magnesium and calcium dialysate concentrations has been investigated in haemodialysis (HD) and peritoneal dialysis (PD). Results generally show that dialysate magnesium, at 0.75 mmol/L, is likely to cause mild hypermagnesaemia, results for a magnesium dialysate concentration of 0.5 mmol/L were less consistent, whereas serum magnesium levels were mostly normal to hypomagnesaemic when 0.2 and 0.25 mmol/L were used. While dialysate magnesium concentration is a major determinant of HD or PD patients’ magnesium balance, other factors such as nutrition and medications (e.g. laxatives or antacids) also play an important role. Also examined in this review is the role of magnesium on parathyroid hormone (PTH) levels in dialysis patients. Although various studies have shown that patients with higher serum magnesium tend to have lower PTH levels, many of these suffer from methodological limitations. Finally, we examine the complex and often conflicting results concerning the interplay between magnesium and bone in uraemic patients. Although the exact role of magnesium in bone metabolism is unclear, it may have both positive and negative effects, and it is uncertain what the optimal magnesium levels are in uraemic patients. Oxford University Press 2012-02 /pmc/articles/PMC4455820/ /pubmed/26069820 http://dx.doi.org/10.1093/ndtplus/sfr166 Text en © The Author 2012. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Articles
Cunningham, John
Rodríguez, Mariano
Messa, Piergiorgio
Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
title Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
title_full Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
title_fullStr Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
title_full_unstemmed Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
title_short Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients
title_sort magnesium in chronic kidney disease stages 3 and 4 and in dialysis patients
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455820/
https://www.ncbi.nlm.nih.gov/pubmed/26069820
http://dx.doi.org/10.1093/ndtplus/sfr166
work_keys_str_mv AT cunninghamjohn magnesiuminchronickidneydiseasestages3and4andindialysispatients
AT rodriguezmariano magnesiuminchronickidneydiseasestages3and4andindialysispatients
AT messapiergiorgio magnesiuminchronickidneydiseasestages3and4andindialysispatients